|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
|
18206229 |
2008 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
|
18206229 |
2008 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Survival analysis showed that except VSIG4, other hub genes may be involved in the development of LUAD, in which MYH10, METTL7A, FCER1G and TMOD1 have not been reported previously to correlated with LUAD.
|
31333911 |
2019 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Contrary to VSIG4, we demonstrated that overexpressing let-7g-5p promoted mesenchymal-epithelial transition (MET) and significantly inhibited invasion and migration consistent with the reduction of glioblastoma stem cell phenotypes in U-87MG cells.
|
27634309 |
2016 |
|
Alopecia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic prediction of male pattern baldness.
|
28196072 |
2017 |
|
Arthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
A soluble form of CRIg reversed inflammation and bone loss in two experimental models of arthritis by inhibiting the AP of complement in the joint.
|
17548523 |
2007 |
|
Arthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we further addressed the specificity and assessed the potential for arthritis monitoring using near-infrared fluorescence (NIRF) Cy7-labeled Vsig4 nanobody (Cy7-Nb119).
|
31288389 |
2019 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we review our current understanding of the diverse roles of CRIg in pathogen elimination, anti-microbial immunity and autoimmunity.
|
29573978 |
2018 |
|
Bacterial Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Extracellular stimulation of VSIG4/complement receptor Ig suppresses intracellular bacterial infection by inducing autophagy.
|
27440002 |
2016 |
|
Benign Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
VSIG4 is overexpressed in ovarian cancers compared with that in benign tumors.
|
28498255 |
2017 |
|
Benign Ovarian Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble VSIG4 concentrations were increased in patients with ovarian cancer compared with that in patients with benign ovarian tumors (P = 0.0452).
|
28498255 |
2017 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
V-set and immunoglobulin domain containing protein 4 (VSIG4) was reported to play an important role in tumorigenesis.
|
30288101 |
2018 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
All of these results demonstrate that macrophage-associated VSIG4 is an activator that facilitates lung carcinoma development.
|
24862966 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The correlation between VSIG4 expression and the prognosis of ovarian cancer was analyzed according to the patients' clinicopathologic characteristics.
|
28498255 |
2017 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Contrary to VSIG4, we demonstrated that overexpressing let-7g-5p promoted mesenchymal-epithelial transition (MET) and significantly inhibited invasion and migration consistent with the reduction of glioblastoma stem cell phenotypes in U-87MG cells.
|
27634309 |
2016 |
|
Chronic heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
In an unbiased approach, the top 10 DEGs SERPINA3, SERPINA5, LCN6, LCN10, STEAP4, AKR1C1, STAC2, SPARCL1, VSIG4 and F8 exhibited no overlap in read counts between DON and HF RVs, high sensitivities, specificities, predictive values and areas under the receiver operating characteristic curves.
|
25725476 |
2015 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
In an unbiased approach, the top 10 DEGs SERPINA3, SERPINA5, LCN6, LCN10, STEAP4, AKR1C1, STAC2, SPARCL1, VSIG4 and F8 exhibited no overlap in read counts between DON and HF RVs, high sensitivities, specificities, predictive values and areas under the receiver operating characteristic curves.
|
25725476 |
2015 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Correlation analysis between unexplored hub genes and clinical features of DN suggested that COL6A3, MS4A6A,PLCE1, TNNC1, TNNI1, TNN2, and VSIG4 may involve in the progression of DN.
|
30485525 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inference analysis revealed a role for innate and tolerogenic immune responses (including VSIG4 and IDO1) in EBV(+) PT-DLBCL.
|
23489474 |
2013 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The agonistic VSIG4 antibodies (VG11), acting through NLRP3 and IL-1β suppression, show significant therapeutic efficacy in mouse EAE.
|
30662948 |
2019 |
|
Fulminant hepatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of Vsig4 in mice ameliorates MHV-3-induced viral fulminant hepatitis.
|
29109438 |
2017 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
|
31377205 |
2019 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Contrary to VSIG4, we demonstrated that overexpressing let-7g-5p promoted mesenchymal-epithelial transition (MET) and significantly inhibited invasion and migration consistent with the reduction of glioblastoma stem cell phenotypes in U-87MG cells.
|
27634309 |
2016 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
|
31377205 |
2019 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Contrary to VSIG4, we demonstrated that overexpressing let-7g-5p promoted mesenchymal-epithelial transition (MET) and significantly inhibited invasion and migration consistent with the reduction of glioblastoma stem cell phenotypes in U-87MG cells.
|
27634309 |
2016 |